Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Mon, 03.03.2025
Formycon AG
Press Release // March 3, 2025
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous formulations in the United States and the European Union
Patient transition to Otulfi® supported by comparable effic [ … ]
Tue, 25.02.2025
Formycon AG
Press Release // February 25, 2025
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
UK market authorization [ … ]
Mon, 24.02.2025
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
Update
Recommendation:
Buy
from:
24.02.2025
Target price:
€46
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analyst Simo [ … ]
Thu, 20.02.2025
Formycon AG
Press Release // February 20, 2025
Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of the comparative data of the ustekinumab biosimilar FYB202 at this year's Congress of the European Croh [ … ]
Mon, 17.02.2025
Formycon AG
Press Release // February 17, 2025
Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon continues FYB206 development without Phase III trial and thus takes pioneering role among pembrolizumab biosimilar developers; investment savings expected to amount to a high double-digit millio [ … ]
Mon, 17.02.2025
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III study ("Lotus") for FYB206 following positive feedback from the U.S. Food and Drug A [ … ]
Wed, 05.02.2025
Formycon AG
Press Release // February 05, 2025
Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Planegg-Martinsried, Germany – Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of FYB203/AHZANTIVE®1 (aflibercept [ … ]
Mon, 20.01.2025
Formycon AG
Press Release // January 20, 2025
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
FYB203 (aflibercept) approved for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
AHZANTIVE® and Baiama® offer patients treat [ … ]
Wed, 15.01.2025
Formycon AG
Press Release // January 15, 2025
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Otulfi®received MHRA approval for both subcutaneous and intravenous formulations, to treat serious inflammatory diseases
UK approval follows the series of successful approvals by the FDA, the European Co [ … ]
Mon, 13.01.2025
Formycon AG
Presse Release // January 13, 2025
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimila [ … ]